Cylwik Bogdan, Naklicki Marcin, Chrostek Lech, Gruszewska Ewa
Department of Biochemical Diagnostics, Medical University of Bialystok, Białystok, Poland.
Acta Biochim Pol. 2013;60(2):151-61. Epub 2013 May 31.
Glycosylation is the most common chemical process of protein modification and occurs in every living cell. Disturbances of this process may be either congenital or acquired. Congenital disorders of glycosylation (CDG) are a rapidly growing disease family, with about 50 disorders reported since its first clinical description in 1980. Most of the human diseases have been discovered recently. CDG result from defects in the synthesis of the N- and O-glycans moiety of glycoproteins, and in the attachment to the polypeptide chain of proteins. These defects have been found in the activation, presentation, and transport of sugar precursors, in the enzymes responsible for glycosylation, and in proteins that control the traffic of component. There are two main types of protein glycosylation: N-glycosylation and O-glycosylation. Most diseases are due to defects in the N-glycosylation pathway. For the sake of convenience, CDG were divided into 2 types, type I and II. CDG can affect nearly all organs and systems. The considerable variability of clinical features makes it difficult to recognize patients with CDG. Diagnosis can be made on the basis of abnormal glycosylation display. In this paper, an overview of CDG with a new nomenclature limited to the group of protein N-glycosylation disorders, clinical phenotype and diagnostic approach, have been presented. The location, reasons for defects, and the number of cases have been also described. This publication aims to draw attention to the possibility of occurrence of CDG in each multisystem disorder with an unknown origin.
糖基化是蛋白质修饰最常见的化学过程,存在于每个活细胞中。这一过程的紊乱可能是先天性的,也可能是后天获得的。先天性糖基化障碍(CDG)是一个迅速增长的疾病家族,自1980年首次临床描述以来,已报告约50种疾病。大多数人类疾病是最近才发现的。CDG是由糖蛋白的N-聚糖和O-聚糖部分合成缺陷以及与蛋白质多肽链的连接缺陷引起的。这些缺陷已在糖前体的激活、呈现和运输、负责糖基化的酶以及控制成分运输的蛋白质中被发现。蛋白质糖基化主要有两种类型:N-糖基化和O-糖基化。大多数疾病是由于N-糖基化途径的缺陷。为方便起见,CDG分为I型和II型。CDG可影响几乎所有器官和系统。临床特征的显著变异性使得识别CDG患者变得困难。诊断可基于异常的糖基化表现。本文概述了仅限于蛋白质N-糖基化障碍组的CDG、临床表型和诊断方法,并描述了其位置、缺陷原因和病例数量。本出版物旨在提醒人们注意在每一种病因不明的多系统疾病中发生CDG的可能性。